Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal condition that causes severe scarring of the lungs. While the pathogenesis of IPF continues to be extensively studied and several factors have been considered, an exact cause has yet to be established. With inadequate treatment options and no cure available, overall disease prognosis is still poor. Existing oral therapies, pirfenidone and nintedanib, may attempt to improve the patients’ quality of life by mitigating symptoms and slowing disease progression, however chronic doses and systemic deliveries of these drugs can lead to severe side effects. The lack of effective treatment options calls for further investigation of restorative as well as additional palliative therapies for IPF. Nanoparticle-based sustained drug delivery strategies can be utilized to ensure targeted delivery for site-specific treatment as well as long-acting therapy, improving overall patient compliance. This review provides an update on promising strategies for the delivery of anti-fibrotic agents, along with an overview of key therapeutic targets as well as relevant emerging therapies currently being evaluated for IPF treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Justice, J. N., Nambiar, A. M., Tchkonia, T., LeBrasseur, N. K., Pascual, R., Hashmi, S. K., Prata, L., Masternak, M. M., Kritchevsky, S. B., Musi, N., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.052 · Cited by 1,261
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Influence of particle size on regional lung deposition – What evidence is there?
Carvalho, T. C., Peters, J. I., & Williams III, R. O. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.12.040 · Cited by 614
Allen, R. J., Porte, J., Braybrooke, R., Flores, C., Fingerlin, T. E., Oldham, J. M., Guillen-Guio, B., Ma, S.-F., Okamoto, T., John, A. E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30387-9 · Cited by 297
Novel mechanisms for the antifibrotic action of nintedanib
Rangarajan, S., Kurundkar, A., Kurundkar, D., Bernard, K., Sanders, Y. Y., Ding, Q., Antony, V. B., Zhang, J., Zmijewski, J., & Thannickal, V. J. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0445oc · Cited by 238
Controlled pulmonary drug and gene delivery using polymeric nano-carriers
Beck-Broichsitter, M., Merkel, O. M., & Kissel, T. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.004 · Cited by 200
Patil-Gadhe, A., Kyadarkunte, A., Patole, M., & Pokharkar, V. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.07.007 · Cited by 84
Pardeshi, S., Patil, P., Rajput, R., Mujumdar, A., & Naik, J. (2021) · Drying Technology · doi:10.1080/07373937.2020.1833213 · Cited by 37
Zhang, Y., MacKenzie, B., Koleng, J. J., Maier, E., Warnken, Z. N., & Williams, R. O. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01085 · Cited by 27
Cited by
Idiopathic pulmonary fibrosis: Current and future treatment
Glass, D. S., Grossfeld, D., Renna, H. A., Agarwala, P., Spiegler, P., DeLeon, J., & Reiss, A. B. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13466 · Cited by 314
Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
Kolb, M., Crestani, B., & Maher, T. M. (2023) · European Respiratory Review · doi:10.1183/16000617.0206-2022 · Cited by 85
Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies
Selvarajah, B., Platé, M., & Chambers, R. C. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101227 · Cited by 57
Maher, T. M., Schlecker, C., Luedtke, D., Bossert, S., Zoz, D. F., & Schultz, A. (2022) · ERJ Open Research · doi:10.1183/23120541.00240-2022 · Cited by 26
Metadata
- Authors
- Ghumman, M., Dhamecha, D., Gonsalves, A., Fortier, L., Sorkhdini, P., Zhou, Y., & Menon, J. U.
- Venue
- European Journal of Pharmaceutics and Biopharmaceutics
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 164
- Pages
- 1-12
- ISSN
- 0939-6411 (ISSN-L)
- OpenAlex
- W3155881139
- Cited by
- 79
- References
- 9
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.